SCHEMBL30775352

SCHEMBL30775352

CN(C)c1ncncc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
CHEK1 O14757 2/20 0.37
AURKA O14965 2/20 0.37
EGFR P00533 2/20 0.36
LRRK2 Q5S007 3/20 0.34
PDPK1 O15530 1/20 0.34
CHEK2 O96017 1/20 0.34
HSP90AA1 P07900 1/20 0.34
HSP90AB1 P08238 1/20 0.34
PRKACA P17612 1/20 0.34
CCNE1 P24864 1/20 0.34
CDK2 P24941 1/20 0.34
MARK3 P27448 1/20 0.34
RPS6KA3 P51812 1/20 0.34
PRKCD Q05655 1/20 0.34
MARK2 Q7KZI7 1/20 0.34
CYP1A2 P05177 4/20 0.33
CYP2D6 P10635 4/20 0.33
MAPK1 P28482 4/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30775268 0.79 CYP11B1 (0.35) CYP11B1CYP11B2CYP1A2CYP2D6MAPK1
SCHEMBL30775391 0.75 EGFR (0.50) EGFR
SCHEMBL24861474 0.74 CHEK1 (0.38) CYP11B1CYP11B2CHEK1AURKAEGFR
SCHEMBL25307259 0.73 CHEK1 (0.37) CYP11B1CYP11B2CHEK1AURKAEGFR
SCHEMBL4880551 0.73 CHEK1 (0.41) CYP11B1CYP11B2CHEK1AURKAEGFR
SCHEMBL26273922 0.72 ALDH1A1 (0.46) CYP11B1CYP11B2CHEK1AURKAEGFR
SCHEMBL30775396 0.72 CSF1R (0.49) EGFRMAPK1HIF1AALDH1A1LMNA
SCHEMBL14541610 0.70 MAPK1 (0.31) CYP11B1CYP11B2MAPK1HSD17B10
SCHEMBL15836142 0.70 AOC1 (0.40) CYP11B1CYP11B2CHEK1AURKAEGFR
SCHEMBL3050114 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US claimed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR CYP11B1 432/4885CYP11B2 234/4885CHEK1 4223/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR CYP11B1 432/4885CYP11B2 234/4885CHEK1 4223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.